Camrelizumab and Rivoceranib Plus HAIC As Conversion Therapy for Potentially Resectable Intermediate-advanced Hepatocellular Carcinoma: a Multicenter, Open-label, Randomized, Phase 2/3 Study
Latest Information Update: 12 Feb 2025
Price :
$35 *
At a glance
- Drugs Camrelizumab (Primary) ; Rivoceranib (Primary)
- Indications Liver cancer
- Focus Therapeutic Use
- Sponsors Jiangsu Hengrui Medicine Co.
- 04 Feb 2025 New trial record